HomeBUSINESS
BUSINESS

FDA Fast-Tracks Astellas’s AML Med Gilteritinib
(Oct.12.2017)

Astellas Pharma said on October 11 that its FLT3/AXL inhibitor gilteritinib has earned the US FDA’s fast-track designation for the treatment of adult patients with FLT3 mutation-positive (FLT3+) relapsed or refractory acute myeloid leukemia (AML) ...
(LOG IN FOR FULL STORY)

News Calendar